help_outline Skip to main content
Add Me To Your Mailing List
Organization of Regulatory and Clinical Associates
Contact Information:
Organization of Regulatory and Clinical Associates
P.O. Box 3490
Redmond, WA 98073
HomeCurrent/Future EventsRegulatory Horizons: What to Expect 2019 and Beyond

Current/Future Events - Event View

This is the "Event Detail" view, showing all available information for this event. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

Regulatory Horizons: What to Expect 2019 and Beyond

When:
Wednesday, January 30, 2019, 8:00 AM until 10:00 AM
Where:
Bellevue Sheraton
Venue website
100 112th Ave NE
Bellevue, WA  98004

(425) 455-3330
Additional Info:
Category:
Regular Monthly Meeting
Registration is closed
Payment in Full In Advance Or At Event
RSVP by Thursday, January 24th, 2019
Registration: 7:30 a.m. – 8:00 a.m. PST
Meeting: 8:00 a.m. – 10:00 a.m. PST

PAID FEES ARE NON REFUNDABLE.

PARKING - Free parking available at the Bellevue Sheraton Hotel on the day of the meeting.

Credit card payments can only be accepted online prior to the meeting. If you plan on paying at the door, please note that the Registration Team can only accept CASH or CHECKS.
No Fee
$60.00

TOPIC: Regulatory Horizons: What to Expect 2019 and Beyond


TOPIC DESCRIPTION: 
Cancer panels, digital health and use of augmented intelligence (AI) are driving rapid changes in regulatory pathways. This presentation will examine the key issues impacting the changing regulatory framework for diagnostics and will provide tips on what is required to obtain successful regulatory approval for these niche products.

Requirements for regulatory submissions, quality management systems and reimbursement are in flux. Key issues impacting near term and future regulatory strategies will be discussed.

The following topics will be covered:
• Current U.S. regulatory activities and requirements for molecular diagnostics
• Biomarker qualification, breakthrough designations, and use of NGS gene panels
• Regulatory and reimbursement convergence – the NGS NCD

SPEAKER: B. Melina Cimler, PhD


SPEAKER BIOGRAPHY: Melina Cimler is the CEO and Founder of PandiaDx LLC. She has over 28 years of experience in the life science and FDA-regulated diagnostic industry leading regulatory, quality systems, clinical affairs, research, and product development organizations with a focus on precision medicine.

Dr. Cimler served as SVP of Regulatory & Quality at Adaptive Biotechnologies until April 2018. In her role, she developed the regulatory strategy for NGS-based immunosequencing products and led regulatory interactions with pharma partners to allow use of NGS-based minimal residual disease tests in oncology drug trials andsubmissions. She was previously Head of Global Quality and VP of Quality, Regulatory, Clinical and Government Affairs at Illumina Inc.

She defined and executed on the regulatory strategy resulting in the first next generation sequencing platform (Illumina’s MiSeqDx) receiving FDA marketing authorization.

She serves on the Board of Directors of Nanostics, Inc., and as a member of the Scientific Advisory Board of M3 Biotechnology. She is an Expert Consultant for NDA Partners.

Previously, she held leadership positions in quality, regulatory and government affairs as SVP at Beckman Coulter Inc. She also served in senior quality, clinical and regulatory roles at Abbott Molecular, Gen-Probe Inc., and C.R. Bard, and as head of Product Development at Epitope, Inc. (now OraSure Technologies). Dr. Cimler holds a Ph.D. in Pharmacology from the University of Washington.


WHO: Clinical, regulatory, quality, manufacturing and legal

This meeting includes:
- Coffee and tea
- Pastries and fresh fruit


Attendance at this meeting may be applied as 1.5 points towards RAC re-certification